Skip to main content
Premium Trial:

Request an Annual Quote

Cobequid and Qiagen Sign Aquaculture Deals

Premium

TORONTO--Cobequid Life Sciences here and the Netherlands-based Qiagen announced an agreement to exploit the potential of DNA vaccines in aquaculture. Cobequid will gain nonexclusive access, limited to use for its aquaculture products, to specific components of Qiagen's proprietary DNA manufacturing technology targeted to gene therapy and genetic vaccination applications.

In a second deal, Cobequid will obtain from Qiagen worldwide exclusive rights under certain patents which cover the use of DNA vaccines in aquaculture to control viral and bacterial diseases and parasitic infections. Cobequid will take over an initial portfolio of five products related to the technologies that have been successfully laboratory tested.

Filed under